Open Nav


Series B and Partnering

  • Date:Wednesday, October 17
  • Time:2:15 PM - 2:30 PM
  • Room:Olympic
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:RECARDIO is a Phase 2 life science company developing the therapeutic platform for drug based regenerative therapies for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival.
  • Company
  • Company HQ City:San Francisco
  • Company HQ Country:United States
  • Company HQ State:California                  
  • CEO/Top Company Official:Roman Schenk
  • Year Founded:2015
  • Main Therapeutic Focus:Cardiovascular
  • Lead Product in Development :Dutogliptin
  • Development Phase of Primary Product:Phase II
  • Previous and Current Investors:family offices
  • Size of Last Investment Round:11m
  • Total Amount Raised to Date, In All Rounds:15m
Roman Schenk